District Of Columbia is currently home to 853 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
NCT04656496
Recruiting
Pediatric cancer survivors are at an increased risk of excessive weight gain and reduced exercise behaviors with the potential for this risk to worsen over time. With over 80% of pediatric cancer patients living to adulthood, many pediatric cancer survivors experience long-term health consequences such as heart disease - the leading cause of death in this population. The purpose of this clinical research study is to teach parents/caregivers skills that will help prevent and reduce the problems... Read More
Gender:
ALL
Ages:
Between 5 years and 14 years
Trial Updated:
12/05/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Obesity, Childhood, Cancer, Survivorship
Register for Updates
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
NCT05476770
Recruiting
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is pre... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
12/04/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Register for Updates
Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia
NCT06722638
Recruiting
Over 90% of children and adolescents diagnosed with acute lymphoblastic leukemia (ALL) will survive long term. Part of the successful treatment that patients receive is the delivery of chemotherapy directly into their spinal fluid via a spinal tap. This takes place approximately 20 times over the course of treatment. Most children and adolescents receive general anesthesia during this procedure to manage pain and anxiety. It is now understood that general anesthesia contributes to impairments in... Read More
Gender:
ALL
Ages:
7 years and above
Trial Updated:
12/03/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Acute Lymphoblastic Leukemia, Pediatric
Register for Updates
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
NCT05285891
Recruiting
This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6,12, 18, and 24. At Month 24, participants will be randomized (2:1) to one of two Arms with randomized treatmen... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/03/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Multiple Sclerosis
Register for Updates
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: a Pragmatic Trial
NCT04372875
Recruiting
We will compare differences in sexually transmitted infection (STI) detection rates between sexual health survey (SHS)-derived electronic clinical decision support (CDS) versus usual care (e.g. no provision of CDS) using an interrupted time series design. We hypothesize that population-based STI detection rates will be higher when SHS-derived electronic CDS is provided compared to usual care. Secondary analysis will include a comparison of STI detection rates by sexual risk strata (high risk vs.... Read More
Gender:
ALL
Ages:
Between 15 years and 21 years
Trial Updated:
12/03/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Sexually Transmitted Diseases
Register for Updates
Vincristine Pharmacokinetics in Infants
NCT05359237
Recruiting
This pilot trial compares drug exposure levels using a new method for dosing vincristine in infants and young children compared to the standard dosing method based on body surface area (BSA) in older children. Vincristine is an anticancer drug used to a variety of childhood cancers. The doses anticancer drugs in children must be adjusted based on the size of the child because children vary significantly in size (height, weight, and BSA) and ability to metabolize drugs from infancy to adolescence... Read More
Gender:
ALL
Ages:
12 years and below
Trial Updated:
12/02/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
NCT05768919
Recruiting
The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed High-Grade Gliomas (HGG).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Glioblastoma
Register for Updates
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Cutaneous Melanoma, Stage II
Register for Updates
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
NCT04337177
Recruiting
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
11/24/2024
Locations: Children's National Research Institute - Children's National Hospital, Washington, District of Columbia
Conditions: Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
Register for Updates
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05354141
Recruiting
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/21/2024
Locations: Direct Biologics Investigational Site, Washington, District of Columbia
Conditions: Acute Respiratory Distress Syndrome, ARDS
Register for Updates
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: MedStar Health Research Institute, Georgetown University, Washington, D.C., District of Columbia
Conditions: Myocarditis Acute, Cancer
Register for Updates
Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)
NCT02998710
Recruiting
The purpose of the study is to characterize the clinical course of homocystinuria in pediatric and adult patients aged 1 to 65 years under current clinical management practices
Gender:
ALL
Ages:
Between 1 year and 65 years
Trial Updated:
11/19/2024
Locations: Travere Investigational Site (Enrolling 1 to <5 Year-olds Only), Washington, District of Columbia
Conditions: Homocystinuria Due to CBS Deficiency
Register for Updates